Scalper1 News
The dropout rate for patients on Gilead Sciences’ hepatitis C treatment Sovaldi is quadruple what was seen during clinical trials, data showed Wednesday. CVS Health (CVS) Research Institute researchers found that real-world use of Gilead’s (GILD) blockbuster drug reflects an 8.1% discontinuation rate vs. an approximate 2% rate in trials. The study also found that patients new to the hepatitis C treatment were less likely to complete Scalper1 News
Scalper1 News